Pfizer Inc. (NYSE:PFE) Shares Sold by Bruce & Co. Inc.

Bruce & Co. Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 1.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 271,900 shares of the biopharmaceutical company’s stock after selling 4,500 shares during the quarter. Pfizer makes up 2.3% of Bruce & Co. Inc.’s holdings, making the stock its 15th largest holding. Bruce & Co. Inc.’s holdings in Pfizer were worth $7,214,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Swedbank AB lifted its stake in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. United Bank lifted its position in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares in the last quarter. Prospera Financial Services Inc boosted its stake in Pfizer by 1.1% in the 3rd quarter. Prospera Financial Services Inc now owns 109,731 shares of the biopharmaceutical company’s stock worth $3,177,000 after purchasing an additional 1,169 shares during the period. Avior Wealth Management LLC grew its position in Pfizer by 1.6% during the 3rd quarter. Avior Wealth Management LLC now owns 52,177 shares of the biopharmaceutical company’s stock worth $1,510,000 after purchasing an additional 798 shares in the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new stake in Pfizer during the 3rd quarter valued at $2,123,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.17 on Friday. The stock has a market capitalization of $148.29 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61. The business has a 50-day moving average of $26.18 and a two-hundred day moving average of $27.07. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the company earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on PFE shares. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.